European Journal of Clinical Pharmacology

, Volume 29, Issue 2, pp 131–147 | Cite as

Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man

  • A. Wellstein
  • D. Palm
  • H. F. Pitschner
  • G. G. Belz
Originals
Received:
Accepted:

Summary

In a double-blind, placebo-controlled study in 6 healthy volunteers, the correlation between beta-adrenoceptor binding, the time course of the effect and plasma concentration kinetics was investigated from 0 to 48 h after a single oral dose of propranolol 240 mg. First, the in vitro beta-adrenoceptor interaction of propranolol was investigated. Propranolol inhibited beta-adrenoceptor binding to rat parotid (beta1) and reticulocyte (beta2) membranes in the presence of pooled human plasma with a Ki of about 8 ng/ml plasma. After oral administration of 240 mg propranolol, concentration kinetics in plasma could be described by a Bateman function with a fictive concentration at time 0 of 275 ng/ml plasma, and a mean elimination half-life of 3.5 h. Using the concentration kinetics of propranolol in plasma together with its in vitro beta-adrenoceptor binding characteristics in the presence of placebo plasma from each individual, the time course of antagonism against beta-adrenoceptor mediated effects was predicted. The latter was in agreement with the time course of propranolol-induced inhibition of tachycardia due to orthostasis. After bicycle ergometry, however, the time course of inhibition of tachycardia was shorter than was predicted. Plasma sampled at various times after propranolol administration inhibited beta-adrenoceptor binding of the radioligand 3H-CGP 12177 to rat reticulocyte membranes in a fashion reflecting the time course of inhibition of exercise tachycardia observed in the volunteers. A direct, linear relation was shown between the in vitro inhibition of beta-adrenoceptor binding by the plasma samples withdrawn after propranolol administration and the inhibition of exercise tachycardia observed in parallel. The results show that the concentrations of antagonist present in plasma are representative of the concentrations in the effect compartment. Deep compartments of drug distribution appear irrelevant to the effects of the drugs. The relation between the plasma concentration of propranolol and the reduction in heart rate at various levels of physical effort shows no significant inhibition at rest and increasing IC50-values from orthostasis to 2 min and to 4 min of ergometry. IC50-values after orthostasis are in the range of the Ki-values from in vitro receptor binding studies, whereas the IC50-values after exercise are shifted 2-to 3-fold to the right relative to the Ki-values. This finding is in agreement with increased beta-adrenoceptor stimulation with increasing effort (release of endogenous noradrenaline), which shifts the antagonist concentration-effect curve to the right. Furthermore, the rightward shift can explain why with increasing effort the time course of the inhibitory effect of propranolol becomes shorter. Release of propranolol from presynaptic stores during exercise is irrelevant, since this would result in opposed effects on the concentration-effect relationship (leftward shift) and the time course of antagonism (longer effect) with increasing work load. It is concluded that the receptor interaction of propranolol together with its plasma concentration kinetics can fully explain the time course of effects after a single oral dose, and so receptor interaction will be the missing link in the correlation between concentration kinetics and effect kinetics of propranolol in man. In general, this mode of correlation should be expandable to any drug exerting its effects according to the law of mass action via receptors in the extracellular space. This approach provides a rational basis for the comparison of different drugs from one group irrespective of their receptor affinity and concentration kinetics.

Key words

propranolol receptor binding kinetics and dynamics in vivo/in vitro correlation beta-adrenoceptors deep compartment 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ariëns EJ (1984) Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 26: 663–668Google Scholar
  2. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48–58Google Scholar
  3. Bonelli (1979) Beta-Rezeptoren-Blockade. Klinische Pharmakologie und klinisch therapeutische Anwendung. Springer, Wien New YorkGoogle Scholar
  4. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205–211Google Scholar
  5. Broadley KJ (1982) Cardiac adrenoceptors. J Auton Pharmacol 2: 119–145Google Scholar
  6. Brodde OE, Engel G, Hoyer D, Bock KD, Weber F (1981) The β-adrenergic receptor in human lymphocytes: Subclassification by the use of a new radio-ligand, (+/-)125-Iodocyanopindolol. Life Sci 29: 2189–2198Google Scholar
  7. Brodde OE, Karad K, Zerkowski HR, Rohm N, Reidemeister JC (1983) Coexistence of β1- and β2-adrenoceptors in human right atrium. Direct identification by (+/-)125-Iodocyanopindolol binding. Circ Res 53: 752–758Google Scholar
  8. Chamberlain DA, Turner P, Sneddon JM (1967) Effects of atropine on heart-rate in healthy man. Lancet 1: 12–15Google Scholar
  9. Chidsey C, Pine M, Favrot L, Smith S, Leonetti G, Morselli P, Zanchetti A (1976) The use of drug concentration measurements in studies of the therapeutic responses to propranolol. Postgrad Med J 52 [Suppl 4]: 26–32Google Scholar
  10. Colburn WA (1981) Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm 9: 367–388Google Scholar
  11. Coltart DJ, Shand DG (1970) Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man. Br Med J 3: 731–734Google Scholar
  12. Cuthbert MF, Collins RF (1975) Plasma levels and β-adrenoceptor blockade with acebutolol, practolol and propranolol in man. Br J Clin Pharmacol 2: 49–55Google Scholar
  13. Daniell HB, Walle T, Gaffney TE, Webb JG (1979) Stimulation-induced release of propranolol and norepinephrine from adrenergic neurons. J Pharmacol Exp Ther 208: 354–359Google Scholar
  14. De Lean A, Hancock AA, Lefkowitz RJ (1982) Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol 21: 5–16Google Scholar
  15. Delhaye M, Taton G, Camus JC, Chatelain P, Robberecht P, Waelbroeck M, Christophe J (1983) Effects of full and partial β-adrenergic agonists and antagonists on human lung adenylate cyclase. Biochem Pharmacol 32: 1831–1835Google Scholar
  16. Fitzgerald JD (1980) Propranolol. In: A Scriabine (ed) Pharmacology of antihypertensive drugs. Raven Press, New York, pp 195–208Google Scholar
  17. Fleming WW, Westfall DP, De la Lande IS, Jellett LB (1972) Lognormal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J Pharmacol Exp Ther 181: 339–345Google Scholar
  18. Gladtke E, v Hattingberg HM (1977) Pharmakokinetik, (2nd edn). Springer, Berlin Heidelberg New YorkGoogle Scholar
  19. Gugler R, Krist K, Raczinski H, Höffgen H, Bodem G (1980) Comparative pharmacodynamics and plasma levels of β-adrenoceptor blocking drugs. Br J Clin Pharmacol 10: 337–343Google Scholar
  20. Hager WD, Pieniascek HJ, Perrier D, Mayersohn M, Goldberger V (1981) Assessment of beta blockade with propranolol. Clin Pharmacol Ther 30: 283–290Google Scholar
  21. Harms HH (1976) Isoproterenol antagonism of cardioselective β-adrenergic receptor blocking agents: A comparative study of human and guinea-pig cardiac and bronchial β-adrenergic receptors. J Pharmacol Exp Ther 199: 329–335Google Scholar
  22. v Hattingberg HM, Brockmeier D, Kreuter G (1977) A rotating iterative procedure (RIP) for estimating hybrid constants. Eur J Clin Pharmacol 11: 381–388Google Scholar
  23. van Herwaarden CLA, Fennis JFM, Binkhorst RA, v'ant Laar A (1977) Haemodynamic effects of adrenaline during treatment of hypertensive patients with propranolol and metoprolol. Eur J Clin Pharmacol 12: 397–402Google Scholar
  24. Hiatt WR, Fradl DC, Zerbe GO, Byyny RL, Nies AS (1984) Selective and nonselective β-blockade of the peripheral circulation. Clin Pharmacol Ther 35: 12–18Google Scholar
  25. Holford NH, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16: 143–166Google Scholar
  26. Hui KKP, Conolly ME, Tashkin DP (1982) Reversal of human lymphocyte β-adrenoceptor desensitization by glucocorticoids. Clin Pharmacol Ther 32: 566–576Google Scholar
  27. Hurwitz GA, Webb JG, Walle T, Bai SA, Daniell HB, Gourley L, Loadholt CB, Gaffney TE (1983) Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol 16: 599–608Google Scholar
  28. Ishizaki T, Tawara K (1978) Comparison of disposititon and effect to timolol and propranolol on exercise tachycardia. Eur J Clin Pharmacol 14: 7–14Google Scholar
  29. Ishizaki T (1980) Likely explanation for longer duration of pharmacological (antianginal) effects of propranolol in relation to its short half-life. Res Commun Chem Pathol Pharmacol 27: 223–239Google Scholar
  30. Israili ZH (1979) Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man. Ann Rev Pharmacol Toxicol 19: 25–52Google Scholar
  31. Kelman AW, Whiting B (1980) Modeling of drug response in individual subjects. J Pharmacokinet Biopharm 8: 115–130Google Scholar
  32. Kopin IJ, Zukowska-Grojec Z, Bayorh MA, Goldstein DS (1984) Estimation of intrasynaptic norepinephrine concentrations at vascular neuroeffector junctions in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 325: 298–305Google Scholar
  33. de Leede GJL, Hug CC, de Lange S, de Boer AG, Breimer DD (1984) Rectal and intravenous propranolol infusion to steady state: Kinetics and β-receptor blockade. Clin Pharmacol Ther 35: 148–155Google Scholar
  34. Lemmer B, Bathe K, Lang PH, Neumann G, Winkler H (1983) Chronopharmacology of β-adrenoceptor-blocking drugs: Pharmacokinetic and pharmacodynamic studies in rats. J Am Coll Toxicol 2: 347–357Google Scholar
  35. Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7: 362–372Google Scholar
  36. Levy G, Gibaldi M (1975) Pharmacokinetics. In: JR Gillette, JR Mitchell, P Randall (eds) Concepts in biochemical pharmacology, part 3. Springer, Berlin Heidelberg New York, pp 4–34Google Scholar
  37. McAinsh J, Baber NS, Smith R, Young J (1978) Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol 6: 115–121Google Scholar
  38. McDevitt DG, Shand DG (1975) Plasma concentrations and the time-course of β-blockade due to propranolol. Clin Pharmacol Ther 18: 708–713Google Scholar
  39. Mullane JF, Kaufman J, Dvornik D, Coelho J (1982) Propranolol dosage, plasma concentration, and β-blockade. Clin Pharmacol Ther 32: 692–700Google Scholar
  40. Okupa FE, Daneshmend TK, Shrosbree E, Roberts CJC (1981) Dose response studies of indenolol, a β-adrenoceptor blocker. Clin Pharmacol Ther 29: 434–439Google Scholar
  41. Platzer R, Galeazzi RL, Niederberger W, Rosenthaler J (1984) Simultaneous modeling of bopindolol kinetics and dynamics. Clin Pharmacol Ther 36: 5–13Google Scholar
  42. Robberecht P, Delhaye M, Taton G, De Neef P, Waelbroeck M, De Smet JM, Leclerc JL, Chatelain P, Christophe J (1983) The human heart β-adrenergic receptors. I. Heterogeneity of the binding sites: Presence of 50% β1- and 50% β2-adrenergic receptors. Mol Pharmacol 24: 169–173Google Scholar
  43. Russell PM, Webb JG, Walle T, Daniell HB, Privitera PJ, Gaffney TE (1983) Adrenergic nerve stimulation-induced release of propranolol from the perfused hindlimb and spleen of the dog and associated changes in postjunctional response. J Pharmacol Exp Ther 226: 324–329Google Scholar
  44. Scriabine A (1979) β-adrenoceptor blocking drugs in hypertension. Ann Rev Pharmacol Toxicol 19: 269–284Google Scholar
  45. Serlin MJ, Orme LE, Baber NS, Sibeon RG, Laws E, Breckenridge A (1980) Propranolol in the control of blood pressure: A dose-response study. Clin Pharmacol Ther 27: 586–592Google Scholar
  46. Stachelin M, Simons P, Jaeggi K, Wigger N (1983) CGP 12177. A hydrophilic β-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem 258: 3496–3502Google Scholar
  47. Stiles GL, Taylor S, Lefkowitz RJ (1983a) Human cardiac β-adrenergic receptors: Subtype heterogeneity delineated by direct radioligand binding. Life Sci 33: 467–473Google Scholar
  48. Stiles GL, Strasser RH, Lavin TN, Jones LR, Caron MC, Lefkowitz RJ (1983b) The cardiac β-adrenergic receptor. Structural similarities of β1 and β2-receptor subtypes demonstrated by photoaffinity labeling. J Biol Chem 258: 8443–8449Google Scholar
  49. Street JA, Webb JG, Bright S, Gaffney TE (1984) Accumulation, subcellular localization and release of propranolol from synaptosomes of rat cerebral cortex. J Pharmacol Exp Ther 229: 154–161Google Scholar
  50. Vukovich A, Foley JE, Brown B, Willard DA, Buckley M, O'Kelly D, Fitzgerald D, Tormey W, Darragh A (1979) Effects of β-blockers on exercise double product (systolic blood pressure × heart rate). Br J Clin Pharmacol 7 [Suppl 2]: 167S-172SGoogle Scholar
  51. Waelbroeck M, Taton G, Delhaye M, Chatelain P, Camus JC, Pochet R, Leclerc JL, De Smet JM, Robberecht P, Christophe J (1983) The human heart β-adrenergic receptors. II. Coupling of β2-adrenergic receptors with the adenylate cyclase system. Molec Pharmacol 24: 174–182Google Scholar
  52. Wellstein A, Jablonka B, Wiemer G, Palm D (1984a) Increase of Bmax-values of β-adrenoceptor sites after chronic treatment with reserpine? Pol J Pharmacol Pharm 36: 261–269Google Scholar
  53. Wellstein A, Palm D, Wiemer G, Schäfer-Korting M, Mutschler E (1984b) Simple and reliable radioreceptor assay for β-adrenoceptor antagonists and active metabolites in native human plasma. Eur J Clin Pharmacol 27: 545–553Google Scholar
  54. Wellstein A, Palm D, Belz GG, Pitschner HF (1985) Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of β-blockers. Drug Res 35: 2–6Google Scholar
  55. Whiting B, Kelman AW (1980) The modeling of drug response. Clin Sci 59: 311–315Google Scholar
  56. Wiemer G, Wellstein A, Palm D, v Hattingberg HM, Brockmeier D (1982) Properties of agonist binding at the β-adrenoceptor of the rat reticulocyte. Naunyn-Schmiedeberg's Arch Pharmacol 321: 11–19Google Scholar
  57. Zacest R, Koch-Weser J (1972) Relation of propranolol plasma level to β-blockade during oral therapy. Pharmacology 7: 178–184Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • A. Wellstein
    • 1
  • D. Palm
    • 1
  • H. F. Pitschner
    • 1
  • G. G. Belz
    • 2
    • 1
  1. 1.Zentrum der PharmakologieKlinikum der J. W. Goethe-UniversitätFrankfurt and WiesbadenGermany
  2. 2.Institut für kardiovaskuläre TherapieFrankfurt and WiesbadenGermany

Personalised recommendations